Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a pharmacist check-in boost medication adherence in diabetes and kidney disease?

NCT ID NCT04190251

Disease control Sponsor: Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tests a support program for people with type 2 diabetes and chronic kidney failure who struggle to take their medications regularly. Participants receive an electronic pill bottle that tracks when they open it, plus short motivational interviews with a pharmacist. The goal is to see if this combination helps them stick to their medication routine over 6 to 12 months, compared to usual care alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Interprofessional medication adherence support program (IMAP) combining electronic monitoring and motivational interviews
What this could lead to
If successful, this program could offer a practical way to help patients with diabetes and kidney disease stick to their medications, potentially improving health outcomes.
What could go wrong
This is a small, single-center study with 73 participants, so results may not apply broadly. The program requires extra pharmacy visits, which may not suit everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

73 people

The number who actually took part.

Started

Apr 2016

Finished

Dec 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * MDRD or CKD-EPI eGFR ≤60 ml/min/1.73m2 or albumin/creatinin \>30mg/mmol * Type 2 diabetes * At least one medication in the following list : oral antidiabetics and/or statins and/or antihypertensive drugs and/or aspirin * Patients speaking french, english or italian or interpreter present at each pharmacy visit * Patients have to sign the written consent form * Patients have to agree to use the Electronic Monitoring system (EM, named MEMS®; Aardex Ltd) * Complete laboratory exams in the last 6 months: eGFR and HbA1c and (albumin/creatinin ratio or total cholesterol + LDL + HDL) Exclusion Criteria: * Not being able to understand or sign the consent form * Pregnancy * Recent cancer diagnosis * Cognitive disorder * The subject does not manage the treatment alone

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus, type 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome diabetes mellitus Medication Adherence type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus, type 2 Renal insufficiency chronic

Contacts and locations

Locations

  • Centre Hospitalier Universitaire Vaudois

    Lausanne, Canton of Vaud, 1011, Switzerland

  • Unisante

    Lausanne, Canton of Vaud, 1011, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.